Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut.
Crohn's can affect any part of the gut, though the most common area affected is the end of
the ileum (the last part of the small intestine), or the colon.
Crohn's is a chronic condition. This means that it is ongoing and life-long, although
patients may have periods of good health (remission), as well as times when symptoms are more
active (relapses or flare-ups).
Current available therapies frequently fail to maintain long-term remission and may be
complicated by significant side effects.
There is an unmet medical need for novel therapies. Cellular therapies are emerging as
potentially attractive therapeutic strategies.
The TRIBUTE trial will use autologous regulatory T cells (Tregs) expanded in vitro.
It is hoped that the administration of this treatment to patients with active CD will change
the immune responses in the gut and reduce bowel wall inflammation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
King's College London
Collaborators:
Guy's and St Thomas' NHS Foundation Trust Imperial College London Medical Research Council Miltenyi biotech St. George's Hospital, London